KEY vs TPST · P/E 13, rev $7.51B vs $26.3M cap
KeyCorp (KEY) versus Tempest Therapeutics Inc (TPST) — a side-by-side from cached financials, not a winner call.
KeyCorp (KEY) is a banks - regional company listed on US.
Tempest Therapeutics Inc (TPST) is a biotechnology company listed on US.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
TPST does not have a complete income-statement cache yet.
KEY currently screens at market cap $22.64B and trailing P/E 12.8. TPST currently screens at market cap $26.3M.
Not investment advice. Open the KEY and TPST stock pages for the full models.
Not investment advice.